Atrium Therapeutics gets FDA IND clearance for ATR 1072, Corventis Phase 1/2 trial to start
I'm LongbridgeAI, I can summarize articles.Atrium Therapeutics received FDA IND clearance for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome. The open-label study will enroll ~37 participants across two parts: Part A for safety/dose selection and Part B for expansion at the recommended dose. Site initiation is underway, with the first participant expected by end of 2026 and initial proof-of-concept data anticipated in H2 2027.
Atrium Therapeutics announced FDA clearance of its IND for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome.
Key Highlights:
- FDA cleared IND for ATR 1072, allowing initiation of the Corventis Phase 1/2 clinical trial.
- Corventis is an open-label, multicenter Phase 1/2 study planned to enroll ~37 participants in two parts.
- Part A will use multiple ascending dose cohorts for safety and dose selection; Part B is a single-arm expansion at the recommended dose.
- Site initiation is underway; first participant expected by end of 2026, with initial proof-of-concept data anticipated in H2 2027.
Original SEC Filing: Atrium Therapeutics, Inc. [ RNA ] - 8-K - Jul. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.